XWARONO
Market cap15mUSD
Dec 23, Last price
0.95PLN
1D
-2.27%
1Q
-21.65%
Jan 2017
-15.36%
Name
Onesano SA
Chart & Performance
P/E
—
P/S
5.12
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
10.58%
Rev. gr., 5y
28.40%
Revenues
12m
+0.71%
Net income
-6m
L+61.92%
CFO
-8m
L+60.96%
Profile
onesano S.A. engages in the research and development in the areas of dietetics, animal nutrition, bioremediation, and agrotechnological processes in Poland. The company provides human dietary supplement products under the Estrovita brand. It also offers Yarrowia Equinox; Yarrowia Canifelox; and Yarrowia Farminox; and dietary supplements, food additives, functional foods, and cosmetic raw materials. The company sells its products through chain pharmacies, pharmaceutical wholesalers, bio/eko stores, drugstores, e-commerce, zoological networks, veterinary offices, zoological and veterinary wholesalers, animal feed and supplementary mixture producers, and contract manufacturers. The company was formerly known as Skotan SA and changed its name to onesano S.A. in March 2023. onesano S.A. was founded in 1995 and is based in Chorzów, Poland.
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 12,210 0.71% | 12,124 5.80% | 11,459 9.72% | |||||
Cost of revenue | 18,801 | 14,999 | 3,616 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (6,591) | (2,875) | 7,843 | |||||
NOPBT Margin | 68.44% | |||||||
Operating Taxes | (9) | (116) | (768) | |||||
Tax Rate | ||||||||
NOPAT | (6,582) | (2,759) | 8,611 | |||||
Net income | (6,362) 61.92% | (3,929) 225.52% | (1,207) 1,576.39% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 39,680 | |||||||
BB yield | -74.87% | |||||||
| Debt | ||||||||
Debt current | 111 | 56 | 15,195 | |||||
Long-term debt | 512 | 47 | 51 | |||||
Deferred revenue | 36 | |||||||
Other long-term liabilities | 188 | 23 | 68 | |||||
Net debt | (9,727) | (18,925) | 15,187 | |||||
| Cash flow | ||||||||
Cash from operating activities | (7,681) | (4,772) | (453) | |||||
CAPEX | (738) | (115) | (44) | |||||
Cash from investing activities | (738) | (114) | 236 | |||||
Cash from financing activities | (259) | 23,854 | (53) | |||||
FCF | (9,312) | (3,527) | 10,202 | |||||
| Balance | ||||||||
Cash | 10,350 | 19,028 | 59 | |||||
Long term investments | ||||||||
Excess cash | 9,740 | 18,422 | ||||||
Stockholders' equity | (126,279) | 21,818 | (13,133) | |||||
Invested Capital | 142,186 | 2,789 | 15,263 | |||||
ROIC | 52.83% | |||||||
ROCE | 355.69% | |||||||
| EV | ||||||||
Common stock shares outstanding | 65,880 | 43,298 | 27,000 | |||||
Price | 1.21 -1.55% | 1.22 -20.78% | 1.55 -14.17% | |||||
Market cap | 79,385 49.79% | 52,996 27.04% | 41,715 -41.82% | |||||
EV | 69,658 | 34,071 | 56,902 | |||||
EBITDA | (6,129) | (2,226) | 8,483 | |||||
EV/EBITDA | 6.71 | |||||||
Interest | 320 | 815 | 1,262 | |||||
Interest/NOPBT | 16.09% | |||||||